NasdaqGS:DNLIBiotechs
Denali Therapeutics (DNLI) Stock Could Be 20% Overvalued On Cash Flow Hopes
Denali Therapeutics stock has delivered a 70.2% return over the past year, yet the current checks suggest the market price sits at a premium to its intrinsic value estimate and to what broader valuation metrics would usually flag as a bargain.
The 70.2% one year gain highlights how strongly sentiment has shifted in favor of Denali Therapeutics and raises the bar for what future progress needs to justify.
Expectations around the company’s ability to convert its pipeline into sustainable cash...